The triad FANG vaccine provides a immune-enhancing therapeutic activity by enhancing (i) patient tumor-specific antigen presentation, (ii) DC recruitment, activation and regional nodal migration (GMCSF), and by (iii) reversion of immune tolerance (by blocking furin activation of endogenous TGFβ1 andTGFβ2). The gene discussed is TGFB1; the disease is neoplasm.